The HELLS-MCM5 axis coordinates transcription-replication dynamics to preserve genomic integrity in ALK-negative anaplastic large cell lymphoma.

Authors

Selene Mallia, Giulia Gambarelli, Emanuele Vitale, Veronica Manicardi, Elisa Salviato, Pierluigi Di Chiaro, Rebecca Vezzani, Benedetta Donati, Federica Torricelli, Magda Zanelli, Annalisa Tameni, Ione Tamagnini, Noemi Puccio, Antonino Neri, Alessia Ciarrocchi, Valentina Fragliasso

Published in

Nucleic acids research. Volume 54. Issue 20. Oct 24, 2026.

Abstract

The chromatin remodeler HELLS acts as a pleiotropic guardian of genomic integrity, orchestrating critical processes from DNA replication to DNA damage repair. In anaplastic large cell lymphoma (ALCL), HELLS functions as a transcriptional sentinel, fine-tuning chromatin accessibility and RNA polymerase II kinetics to sustain the oncogenic transcriptional landscape essential for lymphomagenesis. Here we show that HELLS preserves genomic stability and sustains ALK-negative ALCL proliferation by preventing transcription-replication conflicts. HELLS acts as a global regulator of R-loop homeostasis while transcriptionally sustaining MCM5, a core subunit of the replicative MCM2-7 complex, which locally restrains replication-transcription collisions at actively transcribed loci. Mechanistically, HELLS loss reduces MCM5 levels, triggering aberrant firing of origins within transcriptionally active regions and consequent collisions between replication forks and the transcription machinery. Being positioned distally from R-loop-enriched sites, HELLS and MCM5 cooperate to preserve genome integrity, with MCM5 acting as the effector that delivers locus-specific protection against replication-associated genomic instability. Pharmacological or genetic disruption of this axis increases R-loop burden and drastically reduces the survival of ALK-negative ALCL cells, providing a rationale for combination therapy. Collectively, the HELLS-MCM5 module emerges as a master coordinator of transcription-replication dynamics and a novel therapeutic vulnerability in aggressive lymphomas.

PMID:
42960509
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.